VeronikaBachanovaMDPhD
Oncology • Minneapolis, MNHematologic Oncology
Professor of Medicine, University of Minnesota Medical School, Section Head for Malignant Hematology, Director of Hematologic Malignancies Tissue Bank
Dr. Bachanova is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
420 Delaware St Se Ste 5-100
University Of Minnesota
Minneapolis, MN 55455Phone+1 612-626-2663- Is this information wrong?
Summary
- I am a board certified hematologist/oncologist specializing in bone marrow transplantation, cellular therapies and immunotherapies to treat lymphoma and leukemia. My mission to make new promising therapies available to all patients and offer compassionate care at the highest standards. I lead CAR-T program at University of Minnesota.
Education & Training
University of MinnesotaFellowship, Hematology and Medical Oncology, 2004 - 2007
Henry Ford HospitalResidency, Internal Medicine, 1995 - 1998
Comenius UniversityClass of 1992
Certifications & Licensure
MN State Medical License 2006 - 2024
TX State Medical License 1998 - 2005
MI State Medical License 1998 - 1999
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma Start of enrollment: 2005 Aug 24
- Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia Start of enrollment: 2008 Jan 01
- Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701) Start of enrollment: 2009 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Plain language summary of the TRANSFORM study primary analysis results: lisocabtagene maraleucel as a second treatment regimen for large B-cell lymphoma following fail...Jeremy S Abramson, Scott R Solomon, Jon Arnason, Patrick B Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernande...> ;Future Oncology. 2024 Mar 28
- Kikuchi-Fujimoto disease mimicking T-cell lymphoma after COVID-19 vaccination.Linden, M., Sumransub, N., Bachanova, V.> ;American Journal of Clinical Pathology. 2024 Mar 9
- Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma.Gerson, J., Handorf, E., Villa, D., Gerrie, A., Chapani, P., Li, S., Medeiros, L., Wang, M., Cohen, J., Churnetski, M., Hill, B., Sawalha, Y., Hernandez-Ilizaliturri, ...> ;Blood Advances. 2023 Dec 26
- Join now to see all
Journal Articles
- Diffuse Alveolar Hemorrhage Is Most Often Fatal and Is Affected by Graft Source, Conditioning Regiment Toxicity, and Engraftment KineticsErhan H Dincer, Erica D Warlick, Margaret L MacMillan, Patrick Arndt, Daniel J Weisdorf, Nelli Bejanyan, Claudio G Brunstein, Celalettin Ustun, Aleksandr Lazaryan, Ver..., Haematologica
- Five-Year PFS from the AETHERA Trial of Brentuximab Vedotin for Hodgkin Lymphoma at High Risk of Progression or RelapsePatrick Stiff, Edward Agura, Craig H Moskowitz, John Sweetenham, Auayporn Nademanee, Veronika Bachanova, Blood
Abstracts/Posters
- Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell LymphomaVeronika Bachanova, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20+ non-Hodgkin LymphomaVeronika Bachanova, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pat...Veronika Bachanova, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies: Results of phase I-II trial.2019 ASCO Annual Meeting - 6/1/2019
- Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial o...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Clinical Challenges: Managing Hodgkin's in PregnancyDecember 18th, 2020
CAR-NK Cells Make Their Debut in Hematologic CancersMarch 25th, 2020
Gamida Cell Announces Updated Data from Phase 1 Study of GDA-201 to Be Presented at the Annual Meeting of the European Society for Blood and Marrow TransplantationMarch 2nd, 2020- Join now to see all
Hospital Affiliations
M Health Fairview University of Minnesota Medical CenterMinneapolis, Minnesota
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
